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Abstract Thin filament regulation of muscle contraction is
believed to be mediated by both Ca2+ and strongly bound myosin
cross-bridges. We found that secophalloidin (SPH, 5^8 mM)
activates cross-bridge cycling without Ca2+ causing isometric
force comparable to that induced by Ca2+. At saturated [SPH],
Ca2+ further increased force by 20%. SPH-induced force was
reversible upon washing with a relaxing solution. However, there
was more than 30% irreversible loss in subsequent Ca2+-
activated force. We hypothesize that SPH activates muscle via
strongly bound cross-bridges. SPH-activated contraction pro-
vides a new model for studying the role of Ca2+ and cross-bridges
in muscle regulation. 0 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
In resting striated muscles, interaction of myosin cross-
bridges with actin is suppressed by regulatory troponin^tro-
pomyosin complex on the thin ¢lament (for recent reviews see
[1^3]). Binding Ca2þ to troponin C (TnC) results in tropo-
myosin shift over the actin surface and exposure of myosin-
binding sites on the actin previously blocked by tropomyosin.
This switching of the thin ¢lament from the ‘o¡’ to the ‘on’
state allows formation of force-generating myosin cross-
bridges strongly bound to actin. The strongly bound cross-
bridges stabilize the ‘on’ position of tropomyosin, thereby
promoting further actomyosin interaction. Under conditions
that favor strong actin^myosin binding (e.g. low MgATP con-
centrations) muscle can be activated by cross-bridges and con-
tracts without Ca2þ [4]. At physiological MgATP concentra-
tions, the strongly bound cross-bridges formed as a result of
the Ca2þ-induced changes play an important role in muscle
activation. A number of studies suggest that Ca2þ alone is
unable to completely activate the thin ¢lament, but rather
allows the initial cross-bridge binding [5,6]. Thus, maximal
activation requires both Ca2þ binding to TnC and cross-
bridge binding to actin. Great progress in understanding the
synergistic actions of Ca2þ and strongly binding cross-bridges
has been gained by recent studies [7^12]. However, the speci¢c
details of the regulatory mechanism remain to be clari¢ed.
Secophalloidin (SPH), a phalloidin derivative that binds
weakly to actin (for review see [13]), is known to increase
Ca2þ responsiveness of striated muscles [14]. As compared
to other phallotoxins [15^17], SPH has a more pronounced
e¡ect acting at higher concentrations (V25% force increase in
cardiac muscle at full Ca2þ activation with a half-maximal
e¡ect at 0.05^0.07 mM). SPH is unique in that its e¡ect arises
from binding to a site distinct from that of phalloidin. Such
SPH properties arise from hydrolysis of the peptide bond
between the ¢rst and seventh amino acid residues in phalloi-
din, resulting in the opening of the right cycle and appearance
of the C- and N-terminals (Fig. 1).
Here, we report, for the ¢rst time, the ability of SPH
(5^8 mM) to activate force in skinned cardiac muscle without
Ca2þ to a level comparable to that activated by Ca2þ. This
e¡ect also arises from the binding of SPH to a site distinct
from that for phalloidin. The structure^function relationship
of the SPH molecule indicates a critical role of the C-terminal
structure for SPH activity. A strong, Ca2þ-independent acti-
vation may be useful for further studies of the role of Ca2þ
and cross-bridges in muscle regulation.
2. Material and methods
2.1. Preparations of SPH
SPH used in initial experiments was generously provided by Dr. Th.
Wieland (Max-Planck-Institut fu«r Medizinische Forschung, Heidel-
berg, Germany). Subsequently, di¡erent types of SPH (Fig. 1) were
prepared. SPH lactone (SPH-L) was prepared from phalloidin by
incubation with 50% aqueous tri£uoroacetic acid [18]. In preparing
SPH-hydroxy acid (SPH-H-A), lactone was opened by incubation a
water solution of SPH-L (7^8 mg/ml, pH 8.5^8.7 adjusted with
NH4OH) for 70 h at room temperature. Each preparation was
HPLC-puri¢ed. Analytical HPLC of each product on a Beckman
Ultrasphere ODS (C-18) analytical HPLC column (5 Wm; 80 AK ;
4.6U250 mm) resulted in elution of the product as a single peak.
Mass spectroscopy (electrospray ionization; ion trap detector) of
products con¢rmed the expected molecular mass for each preparation.
2.2. Muscle experiments
Left ventricle muscle bundles from fresh bovine heart were obtained
from a local abattoir and skinned with 1% Triton X-100 in rigor [17]
or relaxing solution [19], then stored at 320‡C in solutions containing
50% glycerol.
The experimental set-up and experimental protocols for studying
isometric contraction were previously described [17]. Brie£y, skinned
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muscle bundles (maximal diameter 0.1^0.25 mm and sarcomere length
of 2.1^2.3 Wm) were mounted between a force transducer (AE 801)
and a post, and then placed in a relaxing solution (75 mM KCl, 5 mM
MgCl2, 5 mM ATP, 100 mM MOPS (pH 7.0), 2 mM EGTA, 10 mM
creatine phosphate, 250 U/ml creatine phosphokinase) at 20‡C. To
adjust pCa, 0.1 M CaCl2 was used. Before testing SPH responses,
several contraction^relaxation cycles were performed to evaluate the
muscle preparation and to ensure its stability. Bovine cardiac muscle
preparations are very robust and, after several initial cycles, can with-
stand many contraction^relaxation cycles without considerable loss of
Ca2þ-activated force [17]. Therefore, stable force before SPH applica-
tion was used as the control value.
To study the TnC involvement in SPH e¡ects, TnC was exchanged
by the method of Morimoto and colleagues [20] with some modi¢ca-
tions. Brie£y, muscles were incubated in 2 ml of a continuously agi-
tated solution containing 5 mM trans-1,2-cyclohexanediamine-
N,N,NP,NP-tetraacetic acid (CDTA), 40 mM Tris, 15 mM 2-mercap-
toethanol, 0.6 mM NaN3, 0.2 mM phenylmethylsulfonyl £uoride,
1 mg/ml pepstatin A (pH 8.4) for 80 min, the solution being renewed
every 10 min. For reconstitution, muscles were incubated for 3^5 min
in the relaxing solution with 0.1 mM dithiothreitol and 0.3 mg/ml
bovine cardiac TnC kindly provided by Drs. H.M. Rarick and R.J.
Solaro.
Results are presented as meansTS.E.M.
3. Results
3.1. Ca2þ-independent SPH-induced muscle activation
SPH-H-A added to a skinned muscle in a relaxing solution
induced a large force (Fig. 2) comparable to maximal Ca2-
activated force (100T 9%, n=5). At full SPH-H-A activation,
addition of Ca2þ further increased force by 20T5% (n=4).
2,3-Butanedione monoxime (BDM) and phalloidin, which
modulate force generated by cycling cross-bridges, were used
to test the origin of the SPH-H-A-induced force. Exposure to
30 mM BDM caused a rapid and pronounced (V75%) loss of
SPH-induced force (two experiments). Exposing muscle that
was partially activated by SPH-H-A (1 mM) to phalloidin
(80 WM) further increased force by V30% (two experiments).
We conclude that SPH-H-A activates cross-bridge cycling.
To further assess the role of Ca2þ in the SPH e¡ect, muscles
were partially activated by SPH-H-A in the relaxing solutions
at di¡erent pCa (made by changing EGTA concentration with
compensatory change in KCl concentration to keep the ionic
strength constant). In two such experiments, the force acti-
vated by SPH-H-A at 10 mM EGTA was 94% and 106% of
that generated by the same muscle at 2 mM EGTA. Thus,
SPH-induced muscle activation is Ca2þ-independent.
SPH-induced force was practically reversed by washing, but
subsequent Ca2þ-activated force was considerably reduced
(Fig. 2, 67 T 3% of initial force, n=4). This reduction in
Ca2þ-activated force could not be restored by repeated wash-
ing with relaxing solution, by cycling between relaxing and
activating solutions, by incubation with dithiothreitol, or by
incubation with exogenous cardiac bovine TnC. Furthermore,
force was not restored by TnC extraction and reconstitution
with exogenous TnC (Fig. 3). Thus, force reduction was ap-
parently irreversible and not mediated via an e¡ect on TnC.
3.2. Role of the phalloidin site in SPH e¡ects
SPH retains about 3% of phalloidin a⁄nity to the speci¢c
actin site [21]. To probe a role of the phalloidin site in the
observed SPH-H-A e¡ects on force, SPH-H-A responses were
assessed in muscle pretreated with phalloidin. Pretreatment
with phalloidin, which binds practically irreversibly to actin,
prevented the response of Ca2þ-activated muscle to all phal-
lotoxins, except SPH [14^17]. In the present study, pretreat-
ment with phalloidin did not prevent the Ca2þ-independent
Fig. 1. Chemical structures of secophalloidins. Figures in italics indi-
cate numbers of amino acid residues.
Fig. 2. Representative experiment comparing SPH-H-A- and Ca2þ-
activated contraction. First two contractions are controls.
Fig. 3. E¡ect of TnC extraction followed by reconstitution on the
force generated by muscle in which force had been preliminarily
suppressed by SPH-H-A. During the ¢rst break in the record, the
muscle was washed with relaxing solution for V20 min. During the
second break in the record, TnC was extracted with CDTA-contain-
ing solution for 80 min (see Section 2.2 for details). First contrac-
tion is control. During the next two contractions, force was sup-
pressed by SPH-H-A. The following three contractions demonstrate
stability of suppressed force. After reconstitution with TnC (the last
contraction), force did not exceed that before TnC extraction.
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SPH-H-A-induced force response or the subsequent depres-
sion of Ca2þ-activated force (Fig. 4). Thus, we conclude
that all SPH-H-A e¡ects originate from binding sites distinct
from the phalloidin site.
3.3. Structure^function relationship in SPH
The transformation of phalloidin to SPH results in the ap-
pearance of C- and N-terminals, which may in£uence force
activation. The roles of these C- and N-terminals were system-
atically assessed (Fig. 5). In each of these experiments, the ¢rst
and the last activation were induced by the same compound
to evaluate stability of the response. The results demonstrated
that the C-terminal structure is critical for SPH muscle acti-
vation. At the same concentration, SPH-L-induced force was
less than 10% of that induced by SPH-H-A. Since the force
response increased with SPH-L concentration and did not
appear to saturate (upper panel of Fig. 5), it is possible that
the hydroxy acid con¢guration at the C-terminal is important
for a⁄nity rather than for the e¡ect of bound compound. On
the other hand, the N-terminal is likely to have no role in the
mechanism of SPH action since acetylation of the terminal
amino group had no signi¢cant e¡ect.
4. Discussion
The main ¢nding of this study is Ca2þ-independent activa-
tion of cardiac muscle by SPH. Striated muscle can be acti-
vated by both Ca2þ and cross-bridges strongly bound to actin
[1^3]. Therefore, two distinct mechanisms might exist for the
Ca2þ-independent activation of cardiac muscle by SPH. One
possibility is that SPH acts on the Ca2þ route directly by
changing actin^tropomyosin^troponin interactions and there-
by promoting, for example, a transition from the ‘o¡’ to the
‘on’ actin states without Ca2þ. A second possibility is a SPH-
induced strengthening of actomyosin interaction at a given
state of thin ¢lament activation thereby promoting strongly
bound cross-bridges which in turn can further activate the
thin ¢lament.
In the present study, we observed that maximal SPH-H-A-
induced force was further increased (V20%) by Ca2þ. Previ-
ously, we found that maximal Ca2þ-activated force was fur-
ther increased (V25%) by SPH [14]. Taken together these
results prove di¡erent, non-competitive mechanisms of muscle
activation by Ca2þ and SPH. Half-maximal force without
Ca2þ was reached at V2 mM SPH (Fig. 2), instead of 50^
70 WM SPH at full Ca2þ activation [14]. Earlier we found
V0.7 pCa units leftward shift of the force^pCa curve induced
by 1 mM SPH [22]. Thus, there is a strong positive reciprocal
interaction between SPH and Ca2þ, probably involving
changes in inter-protein interactions.
Non-competitive relationship between Ca2þ and SPH is
consistent with a direct strengthening of the actomyosin inter-
action by SPH. The mutual increase in sensitivity also might
account for the direct action of SPH on the actomyosin bond,
since there is a pronounced feedback between strongly bound
cross-bridges and Ca2þ activation in cardiac muscle [23]. In
support of this idea, our SPH-H-A preparation was found to
reduce ATPase activity of acto-S1 by 30^50% (S.S. Lehrer,
personal communication), indicating SPH sensitivity of acto-
myosin itself.
To summarize, SPH activates cardiac muscle without Ca2þ.
This property of SPH may make it a valuable tool to study
the regulation of muscle contraction. Although the mecha-
nism of SPH activation remains to be determined, SPH might
activate muscle directly by changing actomyosin interaction.
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